Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. is a biotechnology company primarily focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. Founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania, Inovio is dedicated to attempting groundbreaking work in addressing infectious diseases, cancer, and diseases where treatment options are limited. Inovio utilizes its proprietary DNA medicine platform to potentially develop immunotherapies that are precisely targeted to stimulate robust immune responses in the human body. The company is notable within the healthcare sector for its innovative approach to preventive and therapeutic solutions. Its portfolio includes ongoing developments in vaccines targeting broad public health concerns, such as human papillomavirus (HPV)-related diseases and specific cancers. Inovio Pharmaceuticals plays a significant role in the biotechnology landscape by striving to produce novel treatments that may improve vaccine efficacy and broaden the scope of immunotherapy applications, positioning itself as a pivotal player in advancing medical treatments through genetic medicine.